Table 2.

Efficacy results during the OLTP

	EM (N=155)	CM (N=99)	Total (N=254)
Change from baseline in MMD, mean (SE)
Week 24*	n=78 –3.0 (0.4)	n=51 –5.2 (0.8)	n=129 –3.8 (0.4)
Week 36	n=153 –3.7 (0.3)	n=93 –8.0 (0.6)	n=246 –5.3 (0.3)
Week 52	n=147 –3.4 (0.3)	n=96 –6.9 (0.6)	n=243 –4.7 (0.3)
Change from baseline in MSMD, mean (SE)
Week 24*	n=78 –2.1 (0.4)	n=51 –3.4 (0.7)	n=129 –2.6 (0.4)
Week 36	n=153 –2.8 (0.3)	n=93 –5.2 (0.5)	n=246 –3.7 (0.3)
Week 52	n=147 –2.4 (0.3)	n=96 –4.6 (0.5)	n=243 –3.3 (0.3)
Achievement of ≥50% MMD response, n (%)
Week 24*	n=78 31 (39.7)	n=51 13 (25.5)	n=129 44 (34.1)
Week 36	n=153 90 (58.8)	n=93 40 (43.0)	n=246 130 (52.8)
Week 52	n=147 68 (46.3)	n=96 40 (41.7)	n=243 108 (44.4)

Efficacy by EM and CM subgroups at week 24 of the DBTP and during the OLTP. N=number of patients in the open-label analysis set; n=number of patients with observed data.

*Data are shown for patients in the erenumab 70 mg group at week 24 of the DBTP in the efficacy analysis set.

CM, chronic migraine; DBTP, double-blind treatment period; EM, episodic migraine; MMD, monthly migraine days; MSMD, monthly acute migraine-specific medication treatment days; OLTP, open-label treatment period;SE, standard error of the mean;